en
Scientific article
Open access
English

Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits

Published inAnnals of Clinical and Translational Neurology, vol. 4, no. 12, p. 915-920
Publication date2017
Abstract

Rivastigmine has been shown to improve cognition in HIV+ patients with minor neurocognitive disorders; however, the mechanisms underlying such beneficial effect are currently unknown. To assess whether rivastigmine therapy is associated with decreased brain inflammation and damage, we performed T1/T2* relaxometry and magnetization transfer imaging in 17 aviremic HIV+ patients with minor neurocognitive disorders enrolled on a crossed over randomized rivastigmine trial. Rivastigmine therapy was associated with changes in MRI metrics indicating a decrease in brain water content (i.e., edema reabsorption) and/or reduced demyelination/axonal damage. Furthermore, MRI changes correlated with cognitive improvement on rivastigmine therapy.

Citation (ISO format)
PERROTTA, Gaetano et al. Rivastigmine decreases brain damage in HIV patients with mild cognitive deficits. In: Annals of Clinical and Translational Neurology, 2017, vol. 4, n° 12, p. 915–920. doi: 10.1002/acn3.493
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal2328-9503
369views
139downloads

Technical informations

Creation09/04/2018 9:25:00 AM
First validation09/04/2018 9:25:00 AM
Update time03/15/2023 1:08:36 PM
Status update03/15/2023 1:08:36 PM
Last indexation02/12/2024 12:56:00 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack